Cantor Fitzgerald starts coverage of Immunic stock with Overweight rating

Immunic (US4525EP2001) received an Overweight rating when Cantor Fitzgerald initiated coverage on October 23, 2026, according to MarketScreener. Immunic stock was trading at EUR 6.58 at Lang & Schwarz on October 27, 2026 at 6:59 p.m. CEST, up 2.81 percent versus the Tradegate close of October 26, 2026 at EUR 6.40.

Analyst coverage adds a new benchmark

Cantor Fitzgeralds initiation gives Immunic a fresh named analyst view as the biotechnology company advances its late-stage multiple sclerosis program. The rating was reported without a price target, so the central benchmark remains the companys clinical timetable rather than a valuation number.

Immunic expects top-line data from its fully enrolled Phase 3 ENSURE trials in relapsing multiple sclerosis by the end of 2026. The company also expects to initiate an additional Phase 3 trial in progressive multiple sclerosis later in 2026, according to its investor-relations materials.

Cash supports the development plan

Cash and equivalents stood at USD 155.10 million on June 30, 2026. First-half operating cash use was USD 48.30 million, while total liabilities were USD 31.59 million, figures reported in a recent review of Immunics financial position by MerlinTrader.

The second-quarter GAAP net loss was USD 34.10 million, compared with a GAAP net loss of USD 26.82 million in the year-earlier quarter, Markets Insider reported on October 22, 2026. The year-over-year loss increase keeps operating spending central to the investment case.

Price position and key dates

The current euro quote is 2.81 percent above the Tradegate close used for the German market comparison. On the Nasdaq, Immunic last traded at USD 7.33 on October 27, 2026 at 2:02 p.m. ET. The primary-exchange quote remained inside the USD 5.06 to USD 17.43 52-week range, with a market capitalization of USD 100.0 million.

The next major company milestone is the expected ENSURE top-line readout by the end of 2026. Immunic presented new clinical, biomarker and preclinical findings at MSToronto2026 on October 21, 2026, including CALLIPER extension data and additional analyses of vidofludimus calcium.

What the cash figure means

For investors, the USD 155.10 million cash balance is the clearest financial counterweight to the USD 34.10 million second-quarter GAAP loss. The companys Phase 3 timetable supplies the near-term catalyst, while the cash-use figures show why trial execution and financing discipline remain important.

Stock trades above the Tradegate close

Immunic stock stood at EUR 6.58 at Lang & Schwarz on October 27, 2026 at 6:59 p.m. CEST, 2.81 percent above the Tradegate close of October 26, 2026 at EUR 6.40. The further course of trading is shown by the continuously updated real-time quote of Immunic stock.

Market context: Market report Nasdaq Composite.

More news and analyses on Immunic stock